

AACR Virtual Meeting

Precision Medicine Strategies to Improve Therapy of Diffuse Large B-Cell Lymphoma

September 30-October 1, 2021

DISCLOSURE OF FINANCIAL RELATIONSHIPS

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

Relationships are abbreviated as follows: E, Employee of listed company, G, Grant/research support recipient, A, Advisor or review panel member, C, Consultant, S, Stock Shareholder, SB, Speakers' Bureau, H, Honoraria, O, Other.


Last Name	First Name	Company	Relationships	Type	Role
Abramson	Jeremy	Massachusetts General Hospital	Bristol Myers Squibb, Beigene, Mustang, Kite, Ono, Bluebird, Incyte, Genentech, Kymera, Genmab, Epizyme	C,G	Speaker
Advani	Ranjana	Stanford Cancer Center Institute	Forty Seven, Inc./Gilead, Janssen Pharmaceutical, Kura, Merck, Millenium, Regeneron, Seattle Genetics, Cyteir Therapeutics, Bristol Myers Squibb/Celgene, Gilead, Daiichi Sankyo, Inc., Incyte Corporation, Genentech, Roche	A,G	Program Committee, Speaker
Alizadeh	Ash	Stanford University	No Relationships		Speaker
Ansell	Stephen	Mayo Clinic College of Medicine and Science	Bristol Myers Squibb, SeaGen, Takeda, Regeneron, Trillium, ADC Therapeutics	G	Speaker
Arthur	Ronald	American Association for Cancer Research	No Relationships		Staff
Baran	Amy	American Association for Cancer Research	No Relationships		Staff
Hodson	Daniel	University of Cambridge UK	AstraZeneca	G	Speaker
Horning	Sandra	Stanford University School of Medicine	Roche, Gilead Kite	A,S	Speaker
Hutchings	Martin	Copenhagen University Hospital	Celgene, Genmab, Roche, Takeda, Janssen	A,G	Speaker
Kahl	Brad	Washington University in St. Louis	Roche/Genentech, AbbVie/Pharmacyclics, AstraZeneca, Celgene/Bristol Myers Squibb, BeiGene	C,G	Speaker

Precision Medicine Strategies to Improve Therapy of Diffuse Large B-Cell Lymphoma

September 30-October 1, 2021

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	Company	Relationships	Type	Role
Kurtz	David	Stanford University	Foresight Diagnostics, Genentech, Roche	A,C,S	Speaker
Lenz	Georg	University of Münster	Roche, Gilead, Janssen, Bayer, Celgene, Novartis, AstraZeneca, Takeda, Bristol Myers Squibb, NanoString, AbbVie, Incyte, MorphoSys, Genmab, Karyopharm	A,G,O	Program Committee, Speaker
Maus	Marcela	Massachusetts General Hospital	TCR2, Century Therapeutics, Neximmune, Adaptimmune, Agenus, Allogene, Arcellx, Astellas, AstraZeneca, Atara, Bayer, Bristol Myers Squibb, Cabaletta Bio (SAB), Cellectis (SAB), CRISPR therapeutics, In8bio (SAB), Innovakine, Intellia, GSK, Kite Pharma, Micromedicine/BendBio, Novartis, TCR2 (SAB), Tmunity, Torque, and WindMIL (SAB), Servier, Ichnos, Sciences	A,C,G,S,O	Speaker
Melnick	Ari	Weill Cornell Medicine	Sanofi; KDAC, Jubilant, Janssen, ExoTherapeutics, Epizyme, Daiichi, Constellation, Bristol Myers Squibb	A,C,G	Speaker
Nowakowski	Grzegorz	Mayo Clinic College of Medicine and Science	Morphosys, Bantham Pharmaceutical, Daiichi Sankyo, Zai Laboratory, Incyte, Kymera Therapeutics, TG Therapeutics, Blueprint Medicines, Celgene/Bristol Myers Squibb, Roche, Genentech, Nanostrings	C,G	Speaker
Roschewski	Mark	National Cancer Institute	No Relationships		Speaker
Salles	Gilles	Memorial Sloan Kettering Cancer Center	Morphosys, Bristol Myers Squibb/Celgene, Debiopharm, Genentech Roche, Incyte	A,H	Speaker
Scott	David	BC Cancer	AbbVie, AstraZeneca, Bristol Myers Squibb, Incyte, Janssen, NanoString Technologies	C,G,O	Speaker
Sehn	Laurie	BC Cancer	Roche/Genentech, AstraZeneca, AbbVie, Incyte, Kite/Gilead	C,H	Speaker



AACR Virtual Meeting

Precision Medicine Strategies to Improve Therapy of Diffuse Large B-Cell Lymphoma

September 30-October 1, 2021

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	Company	Relationships	Type	Role
Shipp	Margaret	Dana-Farber Cancer Institute	Bristol Myers Squibb, Merck, Immunitas Therapeutics, Bayer, AbbVie, AstraZeneca	A,G	Speaker
Smith	Sonali	University of Chicago	Bristol Myers Squibb, Gilead, ADC Therapeutics, Adaptive	C	Speaker
Staudt	Louis	National Cancer Institute	No Relationships		Program Committee, Speaker
Trotman	Judith	University of Sydney	Roche, Beigene, Takeda, Janssen, PCYC, Celgene/Bristol Myers Squibb	G	Speaker
Westin	Jason	The University of Texas MD Anderson Cancer Center	Kite/Gilead, Novartis, Bristol Myers Squibb, Morphosys, AstraZeneca	C,G	Speaker
Wilson	Wyndham	National Cancer Institute	No Relationships		Program Committee, Speaker
Witzig	Thomas	Mayo Clinic College of Medicine and Science	Celgene	G	Speaker